Tonix Pharmaceuticals Holding Corp. last reported quarterly results on Oct 15, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026). It usually reports 15–41 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 2, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Feb 3, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 15–41 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 15, 2026
15 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
—
|
—
|
—
|
|
Aug 10, 2026
41 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
14
+577.9%
|
-41
-43.4%
|
-2.44
+36.8%
|
|
May 1, 2026
31 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
7
+183.2%
|
-40
-138.8%
|
-2.93
-3.2%
|
|
Feb 3, 2026
34 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
5
+108.8%
|
-47
-112.2%
|
-3.98
+59.8%
|
|
Oct 27, 2025
27 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
3
+16.6%
|
-32
-125.2%
|
-3.59
+84.2%
|
|
Jul 25, 2025
25 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
2
-9.5%
|
-28
+64.1%
|
-3.86
+99.8%
|
|
Apr 25, 2025
25 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
2
-2.1%
|
-17
-12.7%
|
-2.84
+99.5%
|
|
Feb 3, 2025
34 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
3
-31.7%
|
-22
+19.1%
|
-9.89
-165.5%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TNXP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Berkeley Heights, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1430306
- Former names
- TAMANDARE EXPLORATIONS INC. (until Oct 17, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.